INmune Bio, Inc.
INMB
NASDAQ·Healthcare·Biotechnology·Mkt cap $64.9M
$2.44
▲ +7.49%
P/E
-3.54
Mkt Cap
$64.9M
52-Wk Range
$1.09–$2.50
52-Week Range
$1.09 - $2.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 34.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary innate immune system reprogramming technology platform
- Strategic partnerships with Xencor, University of Pittsburgh, and UCL providing research and development leverage
- Focused pipeline addressing high-unmet medical needs in oncology and neurodegenerative diseases
- Clinical-stage programs with potential for significant market opportunities
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Advancement of INKmune through clinical trials for ovarian cancer and MDS indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+96.8% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying INMB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 6, 2026
Reported EPS of -$0.05 vs -$0.21 consensus (+75.8% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+75.8%
Revenue trend · last 8Q
—
-100%
+257%
—
—
—
-100%
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$50.0K
$0
$0
$0
$0
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How INMB stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related